Gemcitabine

BNF:

Immune System & Malignant Disease

Status:

Do Not Prescribe (DNP)

Decision Date:

May 2016

Comments

DO NOT PRESCRIBE (DNP)⁶: NICE TA 389 - gemcitabine in combination with carboplatin is not recommended for treating the first recurrence of platinum-sensitive ovarian cancer.

 

Black Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

search again